365 related articles for article (PubMed ID: 33038983)
21. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.
Pollyea DA; Kim HM; Stevens BM; Lee FF; Harris C; Hedin BR; Knapp JR; O'Connor BP; Jordan CT; Pietras EM; Tan AC; Alper S
J Leukoc Biol; 2021 Jul; 110(1):197-205. PubMed ID: 33155727
[TBL] [Abstract][Full Text] [Related]
22. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
24. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
[TBL] [Abstract][Full Text] [Related]
25. The significance of spliceosome mutations in chronic lymphocytic leukemia.
Rozovski U; Keating M; Estrov Z
Leuk Lymphoma; 2013 Jul; 54(7):1364-6. PubMed ID: 23270583
[TBL] [Abstract][Full Text] [Related]
26. Splicing Factor Mutations in Cancer.
Bejar R
Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
[TBL] [Abstract][Full Text] [Related]
27. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Taylor J; Lee SC
Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
[TBL] [Abstract][Full Text] [Related]
28. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.
Shiozawa Y; Malcovati L; Gallì A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellström-Lindberg E; Miyano S; Ogawa S; Cazzola M
Nat Commun; 2018 Sep; 9(1):3649. PubMed ID: 30194306
[TBL] [Abstract][Full Text] [Related]
29. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract][Full Text] [Related]
30. [Point mutations of genes encoding proteins involvedin RNA splicing in patients with myelodysplastic syndromes].
Barańska M; Czerwińska-Rybak J; Gil L; Komarnicki M
Pol Merkur Lekarski; 2015 Jan; 38(223):5-10. PubMed ID: 25763580
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
32. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.
Pollyea DA; Harris C; Rabe JL; Hedin BR; De Arras L; Katz S; Wheeler E; Bejar R; Walter MJ; Jordan CT; Pietras EM; Alper S
Haematologica; 2019 Sep; 104(9):e388-e392. PubMed ID: 30846499
[No Abstract] [Full Text] [Related]
34. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
35. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.
Brunner AM; Steensma DP
Hematol Oncol Clin North Am; 2020 Apr; 34(2):379-391. PubMed ID: 32089217
[TBL] [Abstract][Full Text] [Related]
36. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
[TBL] [Abstract][Full Text] [Related]
37. [Ineffective erythropoiesis in myelodysplastic syndrome].
Iwama A
Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
[TBL] [Abstract][Full Text] [Related]
38. Splicing factor mutations in myelodysplasia.
Ogawa S
Int J Hematol; 2012 Oct; 96(4):438-42. PubMed ID: 23054646
[TBL] [Abstract][Full Text] [Related]
39. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
Kataoka N; Matsumoto E; Masaki S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
